Nuvectis Pharma (NVCT) Competitors $6.09 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$6.10 +0.02 (+0.25%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NVCT vs. MNPR, ZVRA, CMPS, SVRA, KALV, NAGE, AQST, SIGA, OPT, and BCYCShould you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Monopar Therapeutics (MNPR), Zevra Therapeutics (ZVRA), COMPASS Pathways (CMPS), Savara (SVRA), KalVista Pharmaceuticals (KALV), Niagen Bioscience (NAGE), Aquestive Therapeutics (AQST), Siga Technologies (SIGA), Opthea (OPT), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry. Nuvectis Pharma vs. Its Competitors Monopar Therapeutics Zevra Therapeutics COMPASS Pathways Savara KalVista Pharmaceuticals Niagen Bioscience Aquestive Therapeutics Siga Technologies Opthea Bicycle Therapeutics Nuvectis Pharma (NASDAQ:NVCT) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings. Do institutionals & insiders believe in NVCT or MNPR? 96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 30.5% of Nuvectis Pharma shares are owned by insiders. Comparatively, 20.5% of Monopar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, NVCT or MNPR? Nuvectis Pharma has a beta of -0.29, indicating that its stock price is 129% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Does the media refer more to NVCT or MNPR? In the previous week, Monopar Therapeutics had 12 more articles in the media than Nuvectis Pharma. MarketBeat recorded 15 mentions for Monopar Therapeutics and 3 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.83 beat Monopar Therapeutics' score of 0.55 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate NVCT or MNPR? Nuvectis Pharma currently has a consensus target price of $15.33, indicating a potential upside of 151.78%. Monopar Therapeutics has a consensus target price of $105.67, indicating a potential upside of 27.99%. Given Nuvectis Pharma's higher possible upside, analysts plainly believe Nuvectis Pharma is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Monopar Therapeutics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is NVCT or MNPR more profitable? Monopar Therapeutics' return on equity of -41.76% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Nuvectis PharmaN/A -150.81% -94.84% Monopar Therapeutics N/A -41.76%-39.49% Which has higher earnings and valuation, NVCT or MNPR? Monopar Therapeutics is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvectis PharmaN/AN/A-$19M-$1.17-5.21Monopar TherapeuticsN/AN/A-$15.59M-$3.33-24.79 SummaryMonopar Therapeutics beats Nuvectis Pharma on 8 of the 14 factors compared between the two stocks. Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCT vs. The Competition Export to ExcelMetricNuvectis PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$155.05M$3.38B$6.13B$10.46BDividend YieldN/A2.30%5.73%4.78%P/E Ratio-5.2122.9385.1527.20Price / SalesN/A440.31573.26177.33Price / CashN/A46.1137.3961.86Price / Book12.1810.5012.396.65Net Income-$19M-$52.47M$3.32B$276.79M7 Day Performance1.33%-0.99%-0.24%-1.51%1 Month Performance-1.93%14.50%9.56%5.45%1 Year Performance-7.73%13.92%71.66%36.24% Nuvectis Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCTNuvectis Pharma2.7125 of 5 stars$6.09flat$15.33+151.8%-6.2%$155.05MN/A-5.218News CoverageMNPRMonopar Therapeutics3.1666 of 5 stars$100.63+1.2%$97.33-3.3%+1,655.7%$613.92MN/A-30.2310Analyst ForecastZVRAZevra Therapeutics2.5835 of 5 stars$10.87+2.0%$24.00+120.9%+40.6%$608.79M$23.61M-51.6520Analyst ForecastGap DownCMPSCOMPASS Pathways2.9421 of 5 stars$6.34+0.8%$16.29+156.8%+15.0%$606.25MN/A-3.43120News CoverageAnalyst ForecastSVRASavara3.0405 of 5 stars$3.44-0.7%$7.50+118.3%-1.4%$601.99MN/A-6.9720Trending NewsAnalyst UpgradeAnalyst RevisionKALVKalVista Pharmaceuticals3.7347 of 5 stars$10.93-7.7%$26.43+141.7%-0.3%$598.70M$1.43M-2.78100NAGENiagen Bioscience3.0549 of 5 stars$7.44+2.5%$13.42+80.4%N/A$593.36M$116.30M35.43120AQSTAquestive Therapeutics2.5885 of 5 stars$5.92-0.8%$10.29+73.6%+50.1%$591.76M$44.13M-8.48160Gap UpSIGASiga Technologies1.8517 of 5 stars$8.19-0.5%N/A+24.9%$587.85M$138.72M7.2640Options VolumeOPTOpthea0.4114 of 5 stars$3.41+7.2%$1.33-60.9%-30.5%$583.11M$30K0.008News CoverageAnalyst ForecastGap UpHigh Trading VolumeBCYCBicycle Therapeutics3.8998 of 5 stars$8.19-2.2%$22.22+171.5%-69.0%$580.10M$19.28M-2.34240News CoverageAnalyst Forecast Related Companies and Tools Related Companies MNPR Alternatives ZVRA Alternatives CMPS Alternatives SVRA Alternatives KALV Alternatives NAGE Alternatives AQST Alternatives SIGA Alternatives OPT Alternatives BCYC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVCT) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The com...Huge Alerts | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
